

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anatara Lifesciences Limited
ABN	41 145 239 872

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Brookes
Date of last notice	13 December 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect – Tarandi 1996 Pty Ltd (new trustee, formerly David & Elisabeth Brookes) atf Dr DL Brookes Personal Superfund & David & Elisabeth Brookes atf Dahlbrook Family Trust
Date of change	Ordinary Shares: 9 July 2024 Options: 9 July 2024

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>Direct: Ordinary Shares: 1,240,000 Ordinary Shares Options: 900,000 at \$0.225 ea; vesting 450,000 16 November 2022 & 450,000 16 November 2023 expire 14 November 2025; and 175,000 Options exercisable at \$0.07 ea expiring 11 December 2025</p> <p>Indirect – Tarandi 1996 Pty Ltd atf Dr DL Brookes Personal Superfund 1,740,002 Ordinary Shares and 396,429 Options exercisable at \$0.07 ea expiring 11 December 2025</p> <p>David & Elisabeth Brookes atf Dahlbrook Family Trust 1,550,000 Ordinary Shares and 285,714 Options exercisable at \$0.07 ea expiring 11 December 2025</p>
<p>Class</p>	<p>Ordinary Shares & Options</p>
<p>Number acquired</p>	<p>Shares Indirect: Tarandi 1996 Pty Ltd atf Dr DL Brookes Personal Superfund 750,000 Ordinary Shares = \$30,000 David & Elisabeth Brookes atf Dahlbrook Family Trust 750,000 Ordinary Shares = \$30,000</p> <p>Unlisted Options: Direct – David Brookes 1,500,000 Options Indirect – David & Elisabeth Brookes atf Dahlbrook Family Trust 1,000,000 Options</p>
<p>Number disposed</p>	<p>Nil</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Shares: \$60,000 Options: Nil</p>

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<p>Direct: Ordinary Shares: 1,240,000 Ordinary Shares Options: 900,000 at \$0.225 ea; vesting 450,000 16 November 2022 450,000 16 November 2023 expire 14 November 2025 175,000 Options exercisable at \$0.07 ea expiring 11 December 2025 1,500,000 Options exercisable at \$0.10 ea expiring 9 July 2028</p> <p>Indirect – Tarandi 1996 Pty Ltd atf Dr DL Brookes Personal Superfund 2,490,002 Ordinary Shares; 396,429 Options exercisable at \$0.07 ea expiring 11 December 2025 David & Elisabeth Brookes atf Dahlbrook Family Trust 2,300,000 Ordinary Shares and 285,714 Options exercisable at \$0.07 ea expiring 11 December 2025; and 1,000,000 Options exercisable at \$0.10 ea expiring 9 July 2028</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issued following Shareholder approval at the General Meeting held on 5 July 2024: Ordinary Shares at \$0.04 each purchased under the T2 Placement Unlisted Options issued exercisable at \$0.10 each; 50% vesting 12 months follow issue date & 50% vesting 24 months follow issue date; expiring 9 July 2028</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
<p>No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed</p>	

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anatara Lifesciences Limited
ABN	41 145 239 872

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Michailidis
Date of last notice	12 December 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	John Michailidis & Helen Michailidis at Michailidis Family Account
Date of change	Ordinary Shares: 9 July 2024 Options: 9 July 2024
No. of securities held prior to change	Indirect: John Michailidis & Helen Michailidis at Michailidis Family Account: 949,999 Ordinary Shares & 250,000 Unlisted Options exercisable at \$0.07 ea expiring 11 December 2025
Class	Ordinary Shares
Number acquired	Indirect: 250,000 Ordinary Shares at \$0.04 each purchased under the T2 Placement 1,000,000 Options issued exercisable at \$0.10 each; 50% vesting 12 months follow issue date & 50% vesting 24 months follow issue date; expiring 9 July 2028
Number disposed	Nil

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Shares: \$10,000 Options: Nil
No. of securities held after change	Indirect: John Michailidis & Helen Michailidis atf Michailidis Family Account: 1,199,999 Ordinary Shares & 250,000 Unlisted Options exercisable at \$0.07 ea expiring 11 December 2025 1,000,000 Unlisted Options exercisable at \$0.10 ea expiring 9 July 2028
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issued following Shareholder approval at the General Meeting held on 5 July 2024: Ordinary Shares at \$0.04 each purchased under the T2 Placement Options issued exercisable at \$0.10 each; 50% vesting 12 months follow issue date & 50% vesting 24 months follow issue date; expiring 9 July 2028

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

For personal use only

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anatara Lifesciences Limited
ABN	41 145 239 872

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Nicholas William Haslam
Date of last notice	7 December 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	Options: 9 July 2024
No. of securities held prior to change	Direct: Nil
Class	Options
Number acquired	Direct: 1,000,000 Unlisted Options issued exercisable at \$0.10 each; 50% vesting 12 months follow issue date & 50% vesting 24 months follow issue date; expiring 9 July 2028
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	Direct: 1,000,000 Unlisted Options issued exercisable at \$0.10 each; 50% vesting 12 months follow issue date & 50% vesting 24 months follow issue date; expiring 9 July 2028
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued following Shareholder approval at the General Meeting held on 5 July 2024: Unlisted Options issued exercisable at \$0.10 each; 50% vesting 12 months follow issue date & 50% vesting 24 months follow issue date; expiring 9 July 2028

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A

+ See chapter 19 for defined terms.

For personal use only

If prior written clearance was provided, on what date was this provided?	N/A
---	-----

For personal use only

+ See chapter 19 for defined terms.